Held by 5 specialist biotech funds
High Convergence# Signal Note: Avoro Initiates $1.1B Position in MDGL Avoro's substantial entry suggests confidence in resmetirom (MDGL's GLP-1-independent NASH therapeutic), likely ahead of near-term regulatory catalysts—the drug achieved primary endpoint in Phase 2b with significant liver fat reduction and potential for a differentiated safety profile versus GLP-1 agents.
AI analyst context — unlock full analysis
**Signal Note: Baker Bros. Initiates Major Position in Madrigal Pharmaceuticals (MDGL)** Baker Bros.' new ~2.1M share position in MDGL represents a high-conviction bet on Rezdiffra (resmetirom), the first and only FDA-approved therapy for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis — a market estimated at $30B+ peak potential with a massive underdiagnosed patient population. The position size (notably large even by Baker standards, though the reported dollar value appears to reflect a data anomaly) signals confidence in Rezdiffra's commercial ramp, with Street focus on quarterly script trajectory, planned label expansion into compensated cirrhosis (Phase 3 ongoing), and real-world outcomes data as key near-term catalysts. Baker's track record of concentrated, early-commercial-
+ 3more — see how much conviction went in
See the Full Story